Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • Log out
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Pathophysiology/Complications

Relationship Between β-Cell Mass and Fasting Blood Glucose Concentration in Humans

  1. Robert A. Ritzel, MD1,
  2. Alexandra E. Butler, MD1,
  3. Robert A. Rizza, MD2,
  4. Johannes D. Veldhuis, MD2 and
  5. Peter C. Butler, MD1
  1. 1Larry Hillblom Islet Research Center, UCLA David Geffen School of Medicine, Los Angeles, California
  2. 2Division of Endocrinology, Mayo Clinic, Rochester, Minnesota
  1. Address correspondence reprint requests to Peter C. Butler, MD, Larry Hillblom Islet Research Center, UCLA David Geffen School of Medicine, 24-130 Warren Hall, 900 Veteran Ave., Los Angeles, CA 90095-7073. E-mail: pbutler{at}mednet.ucla.edu
Diabetes Care 2006 Mar; 29(3): 717-718. https://doi.org/10.2337/diacare.29.03.06.dc05-1538
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

In type 2 diabetes there is a progressive defect of insulin secretion that precedes the development of hyperglycemia (1). This defect appears to be at least in part due to a deficit in β-cell mass (2–4). Several therapeutic strategies are now being proposed that may reverse the defect in β-cell mass in people with type 2 diabetes, for example glucagon-like peptide 1 or glucagon-like peptide 1–like surrogates (5). However, the relationship between β-cell mass and the blood glucose in humans is uncertain. Here we report the relative β-cell volume in pancreata obtained at autopsy from people with well-documented blood glucose concentrations in life.

RESEARCH DESIGN AND METHODS

Mean β-cell volume, β-cell replication, and β-cell apoptosis for the case subjects included in this analysis have been reported previously (3). Here we now show the individual data points for blood glucose versus relative β-cell volume in obese case subjects who were nondiabetic, had impaired fasting glucose, or had type 2 diabetes. Pancreatic tissue was processed and immunostained for insulin, and the relative β-cell volume was quantified as previously described (3). The relative β-cell volume was used as a surrogate for β-cell mass since whole- pancreas weight is not available.

Selection of the study subjects from autopsy files was previously described (3). In brief, all case subjects included were obese (BMI >27 kg/m2) and either nondiabetic (<110 mg/dl [6.1 mmol/l]) (n = 31, age 66.9 ± 15.2 years, BMI 36.4 ± 6.9 kg/m2), had impaired fasting glucose (≥110 mg/dl [6.1 mmol/l] but <126 mg/dl [7.0 mmol/l]) (n = 19, age 63.1 ± 10.1 years, BMI 36.8 ± 8.6 kg/m2), or were diabetic (≥126 mg/dl [7.0 mmol/l]) (n = 7, age 59.7 ± years, BMI 36.5 ± 5.3 kg/m2). We only included people with type 2 diabetes who were not taking insulin or glucose-lowering oral medications, both of which would have influenced the measured blood glucose concentrations and the relationship of these with β-cell volume.

The relationship between fractional β-cell volume and fasting blood glucose concentration was analyzed by nonlinear regression analysis to establish the best monoexponential fit of the relationship between the fasting blood glucose (dependent variable) and the β-cell volume (independent variable); y = span × exp(−k × X) + plateau and the point of inflection of the hyperbole. ANOVA was used to test for the effect of β-cell volume on fasting blood glucose.

RESULTS

There was a significant relationship between the β-cell volume and fasting blood glucose concentration, with a point of inflection at x = 1.1 ± 0.1%. This relationship is curvilinear (Fig. 1) so that β-cell deficiency beyond 1.1% is associated with a steep increase in blood glucose with each further decrement in β-cell mass.

CONCLUSIONS

We report that in humans there is a curvilinear relationship between the relative β-cell volume (and presumably the β-cell mass) and the fasting blood glucose concentration. The present data reveal a narrow range of blood glucose over a wide range of fractional β-cell volume (up to ∼10%) and then a much wider range of blood glucose values over a narrow range of volumes at low β-cell volumes, with the threshold set by the curve at ∼1.1% defining that difference. The implications of these findings are that there is a much greater tolerance for variance in insulin sensitivity above this threshold and that below-the-threshold variance in insulin sensitivity and functional defects in insulin secretion have a much greater impact on blood glucose.

There are some important limitations with autopsy studies. The numbers of cases are frequently relatively small. The studies are inevitably cross-sectional and retrospective. We and others have presented data suggesting that the decline in β-cell mass in type 2 diabetes is caused by increased β-cell apoptosis (3,6). Therefore, these data suggest that inhibition of β-cell apoptosis to avoid a β-cell deficit might be effective to delay and/or avoid the onset of diabetes. Indeed, both metformin and thiazolidinediones have been reported to inhibit β-cell apoptosis in vitro (6,7) and to delay onset of type 2 diabetes in clinical studies (8,9). The potential mechanisms underlying increased β-cell apoptosis in type 2 diabetes include toxicity from islet amyloid polypeptide oligomer formation, free fatty acids (lipotoxicity), free oxygen radical toxicity and, once hyperglycemia supervenes, glucose-induced apoptosis (glucotoxicity) (10,11).

The steep increase in blood glucose concentration with β-cell deficiency is consistent with the well-known deleterious effects of hyperglycemia per se on β-cell function. These include defective glucose sensing due to reduced glucokinase activity (12), impaired glucose-induced insulin secretion due to increased uncoupling protein two activity (13), and depletion of immediately secretable insulin stores (14). Also, hyperglycemia reduces insulin sensitivity, further compounding the effects of decreased insulin secretion (15). While the present data suggest that relatively small increases in β-cell mass might have useful actions in restoring blood glucose control, it is likely that aggressive normalization of blood glucose concentrations is required to accompany the strategy to increase β-cell mass to overcome the afore mentioned deleterious effects of hyperglycemia as well as glucose-induced β-cell apoptosis.

In conclusion, there is a curvilinear relationship between β-cell mass and fasting blood glucose concentration in humans. These data provide some guidelines for the efforts targeted toward restoring β-cell mass to reverse diabetes, or prevention of diabetes by protection of β-cell mass. The present data describe just one time point. Data regarding movement up or down the currently described curve in humans will only be available if it becomes possible to measure β-cell mass in vivo.

Figure 1—
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1—

Relationship between percentage of pancreas volume occupied by β-cells and fasting plasma glucose in obese humans without insulin or oral antidiabetic treatment. The solid line is derived from nonlinear regression analysis (monoexponential fit, r = 0.50; P < 0.0001 by ANOVA). The dashed vertical lines indicate the mean β-cell area in obese nondiabetic subjects (OND) (right) and the computed inflection point of the curve (left).

Acknowledgments

These studies were funded in part by the National Institutes of Health (DK59579 to P.C.B., DK61539 to P.C.B. and J.D.V., and DK29953 to R.A.R.), the Deutsche Forschungsgemeinschaft (DFG; Ri 1055/1-1), and the Larry Hillblom Foundation (to P.C.B). There were no conflicts of interest in this study.

Footnotes

  • A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

    The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Accepted November 18, 2005.
    • Received August 16, 2005.
  • DIABETES CARE

References

  1. ↵
    UK Prospective Diabetes Study Group: U.K. Prospective Diabetes Study 16: overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes 44: 1249–1258, 1995
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Kloppel G, Lohr M, Habich K, Oberholzer M, Heitz PU: Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv Synth Pathol Res 4: 110–125, 1985
    OpenUrlPubMedWeb of Science
  3. ↵
    Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC: β-Cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 52: 102–110, 2003
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Yoon KH, Ko SH, Cho JH, Lee JM, Ahn YB, Song KH, Yoo SJ, Kang MI, Cha BY, Lee KW, Son HY, Kang SK, Kim HS, Lee IK, Bonner-Weir S: Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab 88: 2300–2308, 2003
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    Nauck MA: Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes. Horm Metab Res 36: 852–858, 2004
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    Marchetti P, Del Guerra S, Marselli L, Lupi R, Masini M, Pollera M, Bugliani M, Boggi U, Vistoli F, Mosca F, Del Prato S: Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. J Clin Endocrinol Metab 89: 5535–5541, 2004
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    Zeender E, Maedler K, Bosco D, Berney T, Donath MY, Halban PA: Pioglitazone and sodium salicylate protect human beta-cells against apoptosis and impaired function induced by glucose and interleukin-1beta. J Clin Endocrinol Metab 89: 5059–5066, 2004
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393–403, 2002
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP: Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 51: 2796–2803, 2002
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Butler AE, Jang J, Gurlo T, Carty MD, Soeller WC, Butler PC: Diabetes due to a progressive defect in β-cell mass in rats transgenic for human islet amyloid polypeptide (HIP Rat): a new model for type 2 diabetes. Diabetes 53: 1509–1516, 2004
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Donath MY, Halban PA: Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications (Review). Diabetologia 47: 581–589
  12. ↵
    Matschinsky FM, Glaser B, Magnuson MA: Pancreatic β-cell glucokinase: closing the gap between theoretical concepts and experimental realities. Diabetes 47: 307–315, 1998
    OpenUrlAbstract
  13. ↵
    Krauss S, Zhang CY, Scorrano L, Dalgaard LT, St-Pierre J, Grey ST, Lowell BB: Superoxide-mediated activation of uncoupling protein 2 causes pancreatic beta cell dysfunction. J Clin Invest 112: 1831–1842, 2003
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    Ritzel RA, Hansen JB, Veldhuis JD, Butler PC: Induction of beta-cell rest by a Kir6.2/SUR1-selective K(ATP)-channel opener preserves beta-cell insulin stores and insulin secretion in human islets cultured at high (11 mM) glucose. J Clin Endocrinol Metab 89: 795–805, 2004
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    Tomas E, Lin YS, Dagher Z, Saha A, Luo Z, Ido Y, Ruderman NB: Hyperglycemia and insulin resistance: possible mechanisms. Ann N Y Acad Sci 967: 43–51, 2002
    OpenUrlPubMedWeb of Science
PreviousNext
Back to top
Diabetes Care: 29 (3)

In this Issue

March 2006, 29(3)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Relationship Between β-Cell Mass and Fasting Blood Glucose Concentration in Humans
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Relationship Between β-Cell Mass and Fasting Blood Glucose Concentration in Humans
Robert A. Ritzel, Alexandra E. Butler, Robert A. Rizza, Johannes D. Veldhuis, Peter C. Butler
Diabetes Care Mar 2006, 29 (3) 717-718; DOI: 10.2337/diacare.29.03.06.dc05-1538

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Relationship Between β-Cell Mass and Fasting Blood Glucose Concentration in Humans
Robert A. Ritzel, Alexandra E. Butler, Robert A. Rizza, Johannes D. Veldhuis, Peter C. Butler
Diabetes Care Mar 2006, 29 (3) 717-718; DOI: 10.2337/diacare.29.03.06.dc05-1538
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • RESEARCH DESIGN AND METHODS
    • RESULTS
    • CONCLUSIONS
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Impact of Type 1 Diabetes in the Developing Brain in Children: A Longitudinal Study
  • Obstructive Sleep Apnea, Glucose Tolerance, and β-Cell Function in Adults With Prediabetes or Untreated Type 2 Diabetes in the Restoring Insulin Secretion (RISE) Study
  • Importance of Intestinal Environment and Cellular Plasticity of Islets in the Development of Postpancreatectomy Diabetes
Show more Pathophysiology/Complications

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.